These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 30862114)
1. The Main Metabolites of Fluorouracil + Adriamycin + Cyclophosphamide (FAC) Are Not Major Contributors to FAC Toxicity in H9c2 Cardiac Differentiated Cells. Reis-Mendes A; Carvalho F; Remião F; Sousa E; Bastos ML; Costa VM Biomolecules; 2019 Mar; 9(3):. PubMed ID: 30862114 [TBL] [Abstract][Full Text] [Related]
2. Doxorubicin Is Key for the Cardiotoxicity of FAC (5-Fluorouracil + Adriamycin + Cyclophosphamide) Combination in Differentiated H9c2 Cells. Pereira-Oliveira M; Reis-Mendes A; Carvalho F; Remião F; Bastos ML; Costa VM Biomolecules; 2019 Jan; 9(1):. PubMed ID: 30634681 [TBL] [Abstract][Full Text] [Related]
3. Comparative In Vitro Study of the Cytotoxic Effects of Doxorubicin's Main Metabolites on Cardiac AC16 Cells Versus the Parent Drug. Reis-Mendes A; Vitorino-Oliveira C; Ferreira M; Carvalho F; Remião F; Sousa E; de Lourdes Bastos M; Costa VM Cardiovasc Toxicol; 2024 Mar; 24(3):266-279. PubMed ID: 38347287 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and cardiotoxicity of doxorubicin and its secondary alcohol metabolite in rats. Zeng X; Cai H; Yang J; Qiu H; Cheng Y; Liu M Biomed Pharmacother; 2019 Aug; 116():108964. PubMed ID: 31102935 [TBL] [Abstract][Full Text] [Related]
5. The anti-cancer drug 5-fluorouracil is metabolized by the isolated perfused rat liver and in rats into highly toxic fluoroacetate. Arellano M; Malet-Martino M; Martino R; Gires P Br J Cancer; 1998; 77(1):79-86. PubMed ID: 9459149 [TBL] [Abstract][Full Text] [Related]
6. Naphthoquinoxaline metabolite of mitoxantrone is less cardiotoxic than the parent compound and it can be a more cardiosafe drug in anticancer therapy. Reis-Mendes A; Gomes AS; Carvalho RA; Carvalho F; Remião F; Pinto M; Bastos ML; Sousa E; Costa VM Arch Toxicol; 2017 Apr; 91(4):1871-1890. PubMed ID: 27629428 [TBL] [Abstract][Full Text] [Related]
7. Pixantrone, a new anticancer drug with the same old cardiac problems? An in vitro study with differentiated and non-differentiated H9c2 cells. Reis-Mendes A; Alves M; Carvalho F; Remião F; Bastos ML; Costa VM Interdiscip Toxicol; 2018 May; 11(1):13-21. PubMed ID: 30181708 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic interactions of breast cancer chemotherapeutics with human doxorubicin reductases. Hofman J; Skarka A; Havrankova J; Wsol V Biochem Pharmacol; 2015 Aug; 96(3):168-78. PubMed ID: 25986883 [TBL] [Abstract][Full Text] [Related]
9. A correlation between cytotoxicity and reductase-mediated metabolism in cell lines treated with doxorubicin and daunorubicin. Bains OS; Szeitz A; Lubieniecka JM; Cragg GE; Grigliatti TA; Riggs KW; Reid RE J Pharmacol Exp Ther; 2013 Nov; 347(2):375-87. PubMed ID: 23995598 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of Carbonyl Reductase 1 Safely Improves the Efficacy of Doxorubicin in Breast Cancer Treatment. Jo A; Choi TG; Jo YH; Jyothi KR; Nguyen MN; Kim JH; Lim S; Shahid M; Akter S; Lee S; Lee KH; Kim W; Cho H; Lee J; Shokat KM; Yoon KS; Kang I; Ha J; Kim SS Antioxid Redox Signal; 2017 Jan; 26(2):70-83. PubMed ID: 27357096 [TBL] [Abstract][Full Text] [Related]
11. Role of metabolites of cyclophosphamide in cardiotoxicity. Kurauchi K; Nishikawa T; Miyahara E; Okamoto Y; Kawano Y BMC Res Notes; 2017 Aug; 10(1):406. PubMed ID: 28807058 [TBL] [Abstract][Full Text] [Related]
12. Total, renal and hepatic clearances of doxorubicin and formation clearance of doxorubicinol in patients with breast cancer: Estimation of doxorubicin hepatic extraction ratio. Pippa LF; Oliveira ML; Rocha A; de Andrade JM; Lanchote VL J Pharm Biomed Anal; 2020 Jun; 185():113231. PubMed ID: 32163849 [TBL] [Abstract][Full Text] [Related]
13. Doxorubicin metabolism and toxicity in human myocardium: role of cytoplasmic deglycosidation and carbonyl reduction. Licata S; Saponiero A; Mordente A; Minotti G Chem Res Toxicol; 2000 May; 13(5):414-20. PubMed ID: 10813659 [TBL] [Abstract][Full Text] [Related]
14. Mitoxantrone is More Toxic than Doxorubicin in SH-SY5Y Human Cells: A 'Chemobrain' In Vitro Study. Almeida D; Pinho R; Correia V; Soares J; Bastos ML; Carvalho F; Capela JP; Costa VM Pharmaceuticals (Basel); 2018 May; 11(2):. PubMed ID: 29734752 [TBL] [Abstract][Full Text] [Related]
15. Cardiotoxicity of cyclophosphamide's metabolites: an in vitro metabolomics approach in AC16 human cardiomyocytes. Dionísio F; Araújo AM; Duarte-Araújo M; Bastos ML; Guedes de Pinho P; Carvalho F; Costa VM Arch Toxicol; 2022 Feb; 96(2):653-671. PubMed ID: 35088106 [TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics of doxorubicin and doxorubicinol in patients diagnosed with non-Hodgkin's lymphoma. Pérez-Blanco JS; Santos-Buelga D; Fernández de Gatta MD; Hernández-Rivas JM; Martín A; García MJ Br J Clin Pharmacol; 2016 Dec; 82(6):1517-1527. PubMed ID: 27447545 [TBL] [Abstract][Full Text] [Related]
17. Mechanisms of Fatal Cardiotoxicity following High-Dose Cyclophosphamide Therapy and a Method for Its Prevention. Nishikawa T; Miyahara E; Kurauchi K; Watanabe E; Ikawa K; Asaba K; Tanabe T; Okamoto Y; Kawano Y PLoS One; 2015; 10(6):e0131394. PubMed ID: 26114497 [TBL] [Abstract][Full Text] [Related]
18. 5-Ethynyluracil (GW776): effects on the formation of the toxic catabolites of 5-fluorouracil, fluoroacetate and fluorohydroxypropionic acid in the isolated perfused rat liver model. Arellano M; Malet-Martino M; Martino R; Spector T Br J Cancer; 1997; 76(9):1170-80. PubMed ID: 9365165 [TBL] [Abstract][Full Text] [Related]
19. Cellular pharmacology of doxorubicinol alone and combined with verapamil in pancreatic cancer cell lines. Chang BK; Brenner DE; Gutman R Anticancer Res; 1989; 9(2):341-5. PubMed ID: 2751259 [TBL] [Abstract][Full Text] [Related]
20. 5-Fluorouracil induces apoptosis in rat cardiocytes through intracellular oxidative stress. Lamberti M; Porto S; Marra M; Zappavigna S; Grimaldi A; Feola D; Pesce D; Naviglio S; Spina A; Sannolo N; Caraglia M J Exp Clin Cancer Res; 2012 Jul; 31(1):60. PubMed ID: 22812382 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]